Akari CEO Says Synthetic Royalties May Be Used To Fund Coversin Trials
Akari Therapeutics will explore novel funding options to pay for Phase III trials of Coversin, its lead asset, derived from a native protein discovered in the saliva of the Ornithodoros moubata tick.
You may also be interested in...
Positive late-stage clinical results involving Ultomiris in a second potential indication suggest Alexion is on the right track to develop new ultra-rare disease therapies with significant commercial potential.
The rare disease specialist’s new CEO is former Baxalta CEO Ludwig Hantson, who takes over the helm immediately after a leadership shakeup coinciding with an audit investigation.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.